lanoconazole

Lanoconazole is an antifungal imidazole drug used primarily for the treatment of fungal skin infections that is potent and orally available. It acts by inhibiting the synthesis of ergosterol in fungal cell membranes, increasing the permeability of fungal cell membranes, leading to cell lysis and death. Lanoconazole exhibits potent antifungal activity against a wide range of pathogenic fungi including yeast, dermatophytes, dermatiaceous fungi, dimorphic fungi, Aspergihs spp., and Candida spp..

(Z)-Lanoconazole is the Z configuration of Lanoconazole, used for investigating dermatophytosis and onychomycosis. It inhibits sterol 14-alpha demethylase, disrupting fungal membrane ergosterol biosynthesis. Lanoconazole is a potent, orally active imidazole antifungal agent with a broad spectrum of activity against fungi both in vitro and in vivo [1] [2].

(Z)-Tyrphostin A51, the Z configuration of Lanoconazole A51, is a potent protein tyrosine kinase (PTK) inhibitor that dose-dependently inhibits the volume-sensitive release of [3 H]taurine in primary astrocyte cultures. It significantly reduces cellular tyrosyl phosphorylation levels and inhibits both basal and EGF-induced human bone cell proliferation [1] [2].